Form 4: Zenas BioPharma Director Receives Stock Option Grant

Director Patrick G. Enright was granted 18,500 stock options in Zenas BioPharma, Inc. with an exercise price of $18.71.

Summary

• Director Patrick G. Enright received a grant of 18,500 stock options for Zenas BioPharma, Inc. (ZBIO).
• The options have an exercise price of $18.71 per share.
• The grant date for these options is June 15, 2026.
• The options are set to expire on June 15, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential future dilution of existing shareholders upon the exercise of these options.

Risks

• Vesting is subject to continued service, creating a dependency on the director's ongoing tenure.

Future Outlook

The options vest 100% on June 15, 2027, provided the director maintains continued service with the company.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to incentivize board members and align governance with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The grant of stock options to directors is consistent with standard compensation packages for early-to-mid stage biopharmaceutical companies.
• The one-year cliff vesting schedule is a common retention mechanism used by peers in the life sciences industry.

Stakeholder Impact

• Minor potential dilution for existing shareholders if options are exercised in the future.

Next Steps

• Vesting of options on June 15, 2027.

Key Dates

Keywords

Zenas BioPharma, ZBIO, Form 4, Stock Options, Insider Trading, Director Compensation